Physician profile

Ryan E Chizner

Interventional Cardiology · Cartersville, GA

NPI 1548529662

$7,273.19

in general payments reported to CMS, 2019-2025

38 companies · $1,916 in 2025

The $1,916 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$5,045.46
Travel and Lodging$369.87
Education$28.11

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Boston Scientific Corporation $1,093.34 2019-2025 Watchman Access System, Watchman Flx, Opticross
E.R. Squibb & Sons, L.L.C. $702.98 2022-2025 Camzyos, Eliquis
Pfizer INC. $554.64 2019-2025
Novartis Pharmaceuticals Corporation $540.95 2022-2025
Abbott Laboratories $475.48 2019-2024 Amplatzer Amulet
Astrazeneca Pharmaceuticals LP $437.50 2019-2025 Farxiga, Lokelma, Wainua
Merck Sharp & Dohme LLC $378.95 2021-2025 Verquvo, Winrevair
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $361.35 2019-2025 Lifevest
Abiomed $361.21 2022-2025 Impella
Amgen INC. $353.33 2019-2025 Repatha, Repatha
Bayer Healthcare Pharmaceuticals INC. $233.62 2022-2025
Medtronic, INC. $191.44 2022-2025 Venaseal, Reveal Linq
Novo Nordisk INC $166.73 2025 Ozempic, Wegovy
Janssen Pharmaceuticals, INC $160.64 2019-2024 Xarelto
Shockwave Medical, INC $146.66 2023-2025 Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter
Show all 38 companies
CompanyGeneral paymentsYearsTop products
Alnylam Pharmaceuticals INC. $128.55 2024-2025 Onpattro
Amarin Pharma, INC. $128.17 2019
Cardinal Health 200 LLC $91.80 2019
Boehringer Ingelheim Pharmaceuticals, INC. $91.39 2021-2023 Jardiance
Agepha Pharma Fz LLC $90.38 2024-2025 Lodoco
Kestra Medical Technology Services, INC. $79.20 2025 Assure Wcd
Scpharmaceuticals INC. $55.89 2023-2024
Esperion Therapeutics, INC. $49.40 2022-2025 Nexletol
Cvrx, INC. $43.72 2024 Barostim Neo System
Lilly USA, LLC $38.51 2025 Zepbound
Regeneron Healthcare Solutions, INC. $37.95 2025 Praluent, Evkeeza
Bard Peripheral Vascular, INC. $33.35 2019
Lexicon Pharmaceuticals, INC. $32.10 2024
Asahi Intecc USA, INC. $31.75 2019
Sanofi-Aventis U.S. LLC $28.28 2024
Bardy Diagnostics, INC. $28.00 2021
Actelion Pharmaceuticals US, INC. $24.35 2025 Opsynvi
Cleerly, INC. $22.72 2025 Cleerly Labs, Cleerly Ischemia
Vital Connect, INC $21.79 2024 Vitalpatch Rtm
Cook Medical LLC $18.39 2021
Kiniksa Pharmaceuticals International, Plc $16.48 2024 Arcalyst
Irhythm Technologies, INC. $14.45 2020
Cardiovascular Systems INC. $7.75 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Ryan E Chizner

$7,273.19

in general payments reported 2019-2025

Years
2019-2025
Top company
Boston Scientific Corporation
Context
The $1,916 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).

https://glasscript.com/doctor/1380908/ryan-e-chizner

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.